University of Pittsburgh Cancer Institute (UPCI)

CCSG Acknowledgement

Required CCSG Acknowledgement

The NCI requires that publications acknowledge the UPCI CCSG support, and they are tracking compliance. If a UPCI CCSG-supported Shared Resource provided data used in your publication, please include the following statement in the acknowledgment section of your publication(s):

"This project used the UPCI [insert name(s) of shared resource(s)] that [is/are] supported in part by award P30CA047904."

Shared Resource Directors: Please make sure to include this statement on all of your order forms, contracts, etc. as a reminder to your users to acknowledge the UPCI CCSG support.


Cellular Products Laboratory (CPL)

CPL dendritic cellsThe CPL makes quality products for tumor vaccines and for cellular and gene therapy of cancer, ranging from large-scale therapeutic products to small cultures for pre-clinical studies, and pilot studies to support development of new cell products using Current Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP) conditions. The lab is CAP inspected, CLIA certified, FACT accredited, and maintains a Facilities Master File with the FDA.

CPL Services

The CPL generates and prepares quality products for tumor vaccines and for cellular and gene therapy of cancer, and has developed the methodological expertise required to support clinical investigations of cellular therapies, including:

  1. Separation and selection of human peripheral blood lymphocyte (PBL) subsets, culture of tumor infiltrating lymphocytes (TIL) or lymph node lymphocytes (LNL) from tumor tissue, and tumor-involved or tumor-draining lymph nodes, respectively
  2. Culture and modification of peripheral blood-derived lymphocytes, including cytokine-activated T cells (killer T cells), activated natural killer cells (A-NK), and purified CD8+ or CD4+ T cells
  3. Culture and expansion of cells derived from normal tissues, e.g., skin or synovium, for use in gene therapy or cellular treatments
  4. Selection and culture of dendritic cells (DC) derived from monocytes in the peripheral blood or from stem cells, using peripheral blood obtained from patients with cancer
  5. Evaluation of cellular products for functional activity and cellular phenotypes
  6. Performance of gene transfer into T cells, fibroblasts, DC, or tumor cells and selection of genetically-modified cells
  7. Adenovirus production for ex vivo use in clinical trials
  8. Expansion of stem cells from neural, mesenchymal and hematopoietic precursors
  9. Formulation of cellular and peptide products for delayed-type hypersensitivity (DTH) testing, vaccination, and intratumoral, intranodal, intralymphatic, or intravenous administration for therapy
  10. Storage and release of products manufactured externally

The CPL pilots preparation of new cellular products and assists investigators in preparation of INDs. Once IRB and FDA approvals are obtained, the CPL produces and delivers therapeutic-grade cells to the bedside. Recently, generation of DC-based vaccines and research associated with therapeutic DC generation have been the effort, representing the majority of CPL production activities.

Development of new procedures and products

The CPL provides translational research and development services that are essential for the implementation of future clinical trials and thus benefit multiple users. Examples of recent developmental efforts include:

  1. Experiments with novel DC maturation cocktails, containing various cytokines to promote more effective antigen presentation to T cells and thus more robust generation of tumor-specific cytotoxic T lymphocytes (CTL) and helper T cells
  2. Manufacture of tolerogenic DC for diabetes
  3. Clinimax-based separation of T cell subsets
  4. Expansion of TALL-104 T cells for adoptive therapy of patients with prostate carcinoma
  5. Expansion of NK-92 cells for immune therapy of patients with acute lymphoblastic leukemia (ALL)
  6. Generation of Epstein-Barr virus (EBV)-specific CTL for treatment of post-transplant lymphoproliferative disorder (PTLD)
  7. Isolation of autologous HIV-1 and its inactivation: vaccine development for HIV-1 patients
  8. Expansion of human neural stem cells
  9. Amplification and purification of a replication-defective adenovirus for ex vivo transduction of DC